Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings

Authors: Joshua M Chevalier* (a), Megan A Hansen* (a), Kyra H Grantz (a, b), Birgitta Gleeson (b), Benjamin Blumel (b), Veronicah Chuchu (b), Shaukat Khan (b), Ntombi Sigwebela (c), Gwendoline Chimhini (d), Felicity Fitzgerald (e), Cecilia Ferreyra† (b), Brooke E Nichols† (a, b, f)

Affiliations:

a. Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
b. FIND, Geneva, Switzerland
c. FIND, Cape Town, South Africa
d. Department of Child Adolescent and Women's Health, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe
e. Department of Infectious Diseases, Imperial College London, London, United Kingdom
f. Department of Global Health, Boston University School of Public Health, Boston, MA, USA

Correspondence: BE Nichols – brooken@bu.edu

*Equal contribution
†Equal contribution

Keywords: neonatal sepsis, bacterial infection, point-of-care, diagnostics, modeling

Abstract:

Background

Sepsis contributes to nearly 50% of neonatal deaths in resource-limited settings. Accurate, timely diagnosis can improve outcomes, reduce inappropriate antibiotic use, and save healthcare costs. We aimed to determine the minimum technical requirements and cost of a point-of-care test (POCT) for neonatal sepsis to be clinically effective in hospitals and community settings in low-resource settings.

Methods

We modeled the diagnosis and treatment of hospitalized neonates and infants at primary care facilities with suspected sepsis. Health outcomes (mortality, hospital stays, and healthcare-associated infections (HAIs)) were compared under empiric treatment with varied blood culture scenarios to a POCT. Test performance, bacterial infection prevalence, and discharge criteria were varied. A threshold economic analysis identified maximum allowable costs for a cost-neutral POCT.

Results

A POCT could reduce neonatal deaths significantly at hospitals (up to 19%) and community levels (up to 70%), compared to baseline, by enabling faster therapy initiation and reducing unnecessary hospitalizations and HAIs. Healthcare costs could drop by 17%-43% in hospitals and 48%-81% in primary care settings. A POCT priced at $21 for hospitals and $3 for community use could remain cost neutral.

Conclusions

A POCT for neonatal sepsis, even with moderate accuracy, could improve outcomes by accelerating diagnosis, supporting antibiotic stewardship, and lowering costs. High sensitivity is essential to minimize deaths from missed diagnoses and delayed antibiotic therapy. Our results suggest 85% sensitivity and 80% specificity for hospitalized neonates and 90% sensitivity, and 70% specificity in primary care settings are the minimum necessary technical requirements for the POCT.

Introduction

Sepsis is a significant cause of neonatal mortality worldwide, accounting for 7.3% of neonatal deaths, disproportionately affecting low- and middle-income countries (LMICs) [1,2]. Diagnosing neonatal sepsis is challenging due to nonspecific symptoms (i.e., fever, irritability) and limited diagnostic resources, particularly in LMICs where blood culture services are often unavailable or unreliable [3]. Without timely and adequate diagnosis, neonates or infants suspected of sepsis are empirically treated with broad-spectrum antibiotics, leading to antibiotic overuse, increased resistance, and unnecessary hospitalization of those without bacterial infections. Antibiotic overuse in this age group can lead to morbidity and mortality, especially in low birthweight or preterm newborns, while also contributing to the growing concern of antimicrobial resistance (AMR) [4,5]. Continued hospitalization of otherwise healthy neonates puts them at risk of healthcare-associated infections (HAIs), a major cause of sepsis [6]. Likewise, in community-level care, no diagnostic tests are available to diagnose infants with possible serious bacterial infections (pSBI). Infants are typically diagnosed clinically, treated with a single dose of antibiotics, and referred to hospitals [7,8]. If referral is not feasible due to distance, cost, and/or time required, antibiotic injections may be provided at the PHC level [9].

New diagnostic tools to quickly identify neonatal sepsis and pSBI could improve care, guide referrals, and reduce misdiagnosis [7,10]. Current biomarker candidates for a point-of-care test (POCT) include C-reactive protein (CRP), procalcitonin (PCT), or Serum Amyloid A (SAA) [11-13]. Clinical algorithms or prediction scores have also been considered [14]. A POCT for neonatal sepsis must attain certain technical specifications (sensitivity/specificity) and a realistic price to be clinically useful and feasibly implemented [7,15]. To understand these minimum

diagnostic criteria and their impact on health-outcomes, we modeled clinical cascades of neonates born in-hospital and infants presenting at PHC facilities suspected of sepsis with current standard-of-care, or a POCT with same-day results. We performed a threshold economic analysis to determine the prices at which POCT implementation would be cost neutral to the health system.

These results supported the development of a Target Product Profile (TPP) for POCTs for neonatal sepsis and pSBI in infants. The TPP identifies two priority use-cases: 1) in hospitals, when newborns are being evaluated for sepsis, and 2) in community (non-hospital) settings, where infants are evaluated for pSBI. The TPP provides guidance for regulatory authorities, manufacturers, ministries of health, and other health programs and stakeholders for test development [10].

Methods

To evaluate the potential impact of a true POCT for neonatal sepsis, we deterministically modeled the diagnosis and clinical care cascade of two cohorts: 1) hospital-born neonates 0-28 days old and 2) infants 0-59 days old presenting for care at the PHC level. Both models are static and parameterized using point estimates from studies in India, Uganda, or other representative countries with available data (**Table 1**) (**Supplement, Text S1-S3)**. Models were built in RStudio 4.3.1, and analyses were conducted using RStudio and Microsoft Excel 16.81.

Cohort 1: Hospitalized neonates

103 The modeled 1,000 hospital-born neonates (0-28 days) suspected of sepsis due to risk factors
104 (early gestational age, low birthweight) or clinical signs indicative of sepsis (fever, difficulty
105 breathing, inconsistent heart rate). Varied parameters included true bacterial prevalence and
106 antibiotic resistance rates, which increased case fatality rates (CFRs) (**Table 1**). **Figure 1A**
107 displays the clinical care cascade of the modeled population. Baseline care involved empiric
108 antibiotic therapy and partial blood culture access, with delayed results (48 hours) reducing
109 clinical utility.
110
111 Under POCT intervention, all neonates with suspected sepsis were tested using the POCT, and
112 only those with a positive result immediately initiated antibiotics, allowing for potential early
113 discharge for neonates testing negative. We considered varying proportions of neonates without
114 true bacterial sepsis eligible for discharge after clinical evaluation and a negative result (blood
115 culture or POCT) to represent well-presenting neonates. Discharge eligibility ranged (23%, 35%,
116 58%) based on the number of neonates discharged within two, three, or five days from a neonatal
117 intensive care unit (NICU) [16]. We assumed neonates with a false-negative result remained
118 hospitalized based on their clinical presentation and received additional diagnostic testing. This
119 created a delay to antibiotic therapy (>0.5 hours), resulting in two additional days spent in the
120 hospital and a 47% increase in the CFR [17,18]. Neonates without a true bacterial infection who
121 received antibiotic therapy from empiric treatment or false-positive results and remained
122 hospitalized were at risk of antibiotic-related morbidities and HAIs. Neonates with a true
123 bacterial infection (true positive) had an average 16-day hospital stay, while neonates without
124 infection (false positive) stayed an average of seven days [16]. Neonates with an HAI spent 11
125 additional days in the hospital, for a total 18-day stay [19].

126

127 ***Cohort 2: Infants in primary health care facilities***

128 We modeled 5,000 infants (0-59 days of age) presenting to PHC facilities with pSBI, categorized
129 by illness severity (**Table 1)** [8,20]. Each pSBI category had an assumed underlying probability
130 of true bacterial infection, which was varied in this analysis. Bacterial prevalence was
131 parameterized lower in fast breathing infants and higher in critically ill infants, compared to
132 infants with clinical severe infection, reflecting correlation between pSBI severity and true
133 bacterial infection [21].

134

135 Under the standard-of-care (WHO guidelines) fast breathing infants 7-59 days of age were
136 treated on-site with oral amoxicillin, while infants with clinical severe infection and critical
137 illness were referred to inpatient care with a pre-referral dose of antibiotics [22] (**Figure 1B**).
138 When referral was not feasible for infants with clinical severe infection or critical illness, we
139 assumed they were treated on-site for up to seven days with WHO-recommended antibiotic
140 regimens. The probability of accepting referral to hospitalization (17%-90%) was varied to
141 reflect differently resourced contexts [8]. CFRs for each pSBI category were derived from the
142 literature (**Table 1**).

143

144 Using the POCT, all infants presenting with critical illness received a referral and a single
145 antibiotic dose regardless of their POCT result, while all fast-breathing infants were treated on-
146 site without referral based on their POCT result. Infants presenting with a clinical severe
147 infection were only referred for higher-level care, with one dose of antibiotics, if their POCT was
148 positive; otherwise, those with a negative POCT remained monitored on-site. False positives

149 with clinical severe infection received referral and treatment, while false negatives had an
150 assumed four-hour delay to antibiotic initiation and increased CFR [17,23].
151
152 Upon referral acceptance, infants entered the hospital model (**Figure 1A**) without additional
153 testing using the POCT. Hospitalized infants without a true underlying bacterial infection were at
154 risk of HAIs, experiencing a higher CFR compared to community-borne infections. These CFRs
155 differed from those in the hospital model because different clinical populations are considered in
156 each model (**Table 1**). Discharge eligibility among community-referred infants without bacterial
157 infection was held constant at 58%.
158
159 ***Outcomes and Sensitivity Analysis***
160 Diagnostic impact was quantified as the percent reduction in deaths and hospital days, and the
161 number of HAIs and antibiotic-associated morbidities prevented through POCT use. Diagnostic
162 impact was assessed across a range of POCT sensitivities (80%-100%) and specificities (70%-
163 100%). Sensitivity analyses were performed to understand the performance of the POCT across
164 several scenarios: varying discharge eligibility, referral acceptance, true bacterial prevalence
165 among pSBI cases (6%, 12%, 24%), and the risk of contracting an HAI (5%-20%). In the
166 community-level analysis, the CFR of HAIs was varied (12%, 29%).

167 ***Economic Analysis***

168 A threshold economic analysis evaluated the total costs of care at baseline and with the POCT to
169 determine at which price the POCT would be cost neutral to the healthcare system including
170 direct and indirect costs (i.e., training, supply chain logistics, quality control), a key
171 characteristic of the TPP. Total inpatient care costs in India and Uganda, representing variation,
172 were gathered from the provider perspective and inflated to 2023 USD (Table 1) [24-26].
173 Healthy infants did not contribute additional costs after discharge. The maximum allowable cost
174 for a POCT in a hospital setting was calculated by dividing hospitalization costs saved using the
175 POCT by the total POCTs administered to achieve cost savings.

176

177 The maximum allowable cost of a POCT at PHCs was also determined using cost savings of
178 community management and administered antibiotics (Table 1) [24-27]. Inpatient care costs at a
179 hospital after referral followed those described for the hospital model. Healthcare costs in
180 Uganda, where community care and referral costs were reduced by 33%, were used as a
181 sensitivity analysis to estimate the maximum cost at which a POCT remained cost-neutral [26].
182 This analysis was also performed excluding infants with critical illness, as their POCT results did
183 not alter clinical practice in the model.

184 **Table 1.** Model parameters for hospital and community settings. **CFR: Case Fatality Rate*

Parameter	Value (%)
Hospital Model	
Prevalence of culture-positive sepsis among suspected cases [21,28] - *High* - *Moderate* - *Low*	 23.6 11.8 5.9
Proportion of infections which are antimicrobial resistant [3]	50.0
Proportion of suspected cases receiving blood culture [21]	59.5
Blood culture sensitivity/specificity [29]	66.7/100
Probability of antibiotic-related morbidities among antibiotic-treated children [29]	27.7
Probability of acquiring hospital-associated infection during hospitalization among children without prior infection [30]	5, 10, 15, 20
CFR*, no infection [3]	8.8
CFR*, antibiotic susceptible infection [3]	29.0
CFR*, antimicrobial resistant infection [3]	54.5
CFR*, delayed antibiotic initiation [17]	68.2
CFR*, antibiotic-associated mortality [31]	0.9
Community Model	
Possible serious bacterial infection [8,9] - *Proportion fast breathing* - *Proportion clinical severe infection* - *Proportion critical illness*	 38.7 53.9 7.3
Bacterial prevalence [3,21,28] - *Weighted average (0.5x, 1.0x, 2.0x)* - *Fast breathing (0.5x)* - *Clinical severe infection (1x)* - *Critical illness (2x)*	 5.2, 10.4, 20.8 3.0, 5.9, 11.8 5.9, 11.8, 23.6 11.8, 23.6, 47.2
CFR* (community-treated) [8] - *Fast breathing* - *Clinical severe infection* - *Critical illness*	 0.1 1.9 14.6
CFR* (hospital-treated) [8,21,32] - *Non-bacterial illness* - *True bacterial infection* - *Healthcare-associated infection*	 2.6 11.5 12.0, 29.0
Referral acceptance [8,9]	17, 37, 69, 90
Cost Assumptions	
Daily cost of treatment and care in tertiary hospital (India) [24,25] - *Non-bacterial illness*	 $96

- *True bacterial infection*	$118
Daily cost of treatment and care in tertiary hospital (Uganda) [25,26] - *Non-bacterial illness* - *True bacterial infection*	 $31 $39
Cost of oral amoxicillin (India) [24,25,27] - *Community-treated* - *Hospital-treated*	 $1.29 $1.88
Cost of oral amoxicillin (Uganda) [25,26] - *Community-treated* - *Hospital-treated*	 $0.43 $0.62
Cost of outpatient visit to hospital after referral (India) [25,27]	$18.16
Cost of outpatient visit to hospital after referral (Uganda) [25,26]	$5.99

185

186 # Results

187 ***Health outcomes of hospitalized neonates following POCT implementation***

188 In the hospital cohort, all neonates suspected of sepsis received empiric antibiotic therapy and
189 60% received blood culture. Blood culture results permitted early discharge of 5%-13% of
190 neonates without true, depending on underlying eligibility (23%-58%). The final mortality rate
191 among neonates who had or developed infection was 41.7%.

192

193 The percentage of neonatal deaths prevented with a POCT was greater with lower underlying
194 bacterial prevalence (6%) and larger proportions of neonates eligible for discharge (58%). In
195 these contexts, test specificity was particularly important to rule out infection among well-
196 presenting neonates. Increasing test specificity reduced HAIs due to earlier discharge of neonates
197 without infection and greater reductions of antibiotic-associated morbidities from fewer false-
198 positive results (**Supplement, Figure S1-S2**). The impact of the POCT increased when HAI risk
199 was higher (20% vs. 5%), as HAIs constituted 28%-66% of total infection related deaths with
200 high risk versus 9%-33% when risk was low (**Figure 2**).

201

202 Yet, in some contexts test sensitivity was the key driver of diagnostic impact. In settings with
203 low HAI risk (5%) and discharge eligibility (23%), but high bacterial prevalence (24%), excess
204 deaths occurred with the POCT compared to baseline (0.2%-1.6% relative increase) when
205 sensitivity was below 85% due to increasing false-negative results and subsequent delays in
206 antibiotic therapy. With 85% sensitivity, a test specificity greater than 80% was required to avoid
207 increased mortality across all contexts (**Figure 2A**).

208 With high HAI risk (20%), a POCT for neonatal sepsis in hospitals led to a net reduction in
209 neonatal deaths (0.3%-19.4% of deaths averted compared to baseline) at all test sensitivities
210 (80%-100%) and specificities (70%-100%) under the varying modeled proportions of bacterial
211 prevalence and discharge eligibility (**Figure 2B**). The percentage of neonatal deaths prevented
212 increased as POCT sensitivity increased, limiting false negatives and reducing delays to
213 antibiotic initiation for infected neonates.
214
215 Earlier discharge leading to reduced HAI opportunity, produced a net reduction in hospital days.
216 Total hospitalization days dropped by 8.2%-50.9% with POCT use **(Supplement, Figure S3**).
217 The percent reduction in hospital days followed similar trends to neonatal deaths, with respect to
218 test specifications, discharge eligibility, and bacterial prevalence, but was not significantly
219 impacted by HAI risk.
220
221 ***Health outcomes of community-presenting infants following POCT implementation***
222 In the modeled PHC cohort of 5,000 infants with pSBI, the proportion of infants correctly
223 referred to upper-level care at baseline (i.e., infants with true bacterial infection) varied from
224 17%-33% as underlying bacterial prevalence increased (6%-24%). The proportion of correct
225 referrals increased from 17% at baseline to 38% upon POCT implementation with the lowest
226 modeled test specifications (80% sensitivity, 70% specificity) when bacterial prevalence was low
227 and from 33% to 58% when bacterial prevalence was high (**Supplement, Figure S4**). The
228 relative impact of the POCT on appropriate referrals largely relied on high test specificity
229 prompting more correct referrals.
230

At baseline, 13-50 infant deaths occurred in PHC clinics and hospitals per 1,000 pSBI episodes across all modeled scenarios (**Supplement, Figure S5**). Mortality increased as underlying bacterial prevalence and referral acceptance increased. Greater referral acceptance led to increased hospital admission of infants without bacterial infection, posing HAI risk. HAI deaths composed between 0.6%-44.7% of total deaths at baseline, depending on other varied parameters (**Supplement, Figure S6**).

A POCT informing hospital referrals reduced total infant deaths when test sensitivity and specificity were sufficiently high (**Figure 3**). The range of scenarios in which deaths increased was greater when HAI risk and mortality were low (5%, 12% respectively) (**Figure 3A**). At low bacterial prevalence and high referral acceptance, and high HAI risk (20%) and mortality (29%), a POCT with high sensitivity and specificity could reduce infant deaths by up to 70% (**Figure 3B**). However, with low sensitivity and specificity, more deaths were observed (3.5%-48%) with lower referral acceptance and higher levels of bacterial prevalence. This was attributable to delayed antibiotic initiation associated with a false-negative POCT.

To limit deaths caused by false-negative results, a high sensitivity of at least 90% could be combined with a lower specificity (70%), reducing total infant deaths across most scenarios. However, under the worst-case scenarios, test sensitivity (≥98%) and specificity (≥95%) would need to be exceedingly high to avoid excess infant mortality.

251 ***Sensitivity Analysis***

252 Univariate sensitivity analyses of parameters in both the hospital and community models, and
253 their relationship with the number of infant deaths averted, stratified by HAI risk, are shown in
254 **Figure 4**. Sensitivity and specificity remained at 85% and 80% in the hospital model, and 90%
255 and 70% in the community model, representing the identified necessary minimum specifications
256 to reduce mortality across most scenarios.

257

258 At the hospital level, increasing test specificity, promoting accurate negative diagnoses, drove
259 reductions in neonatal deaths by earlier discharge and reducing HAIs. HAI risk substantially
260 influenced the potential reductions in mortality; when HAI risk was low, there was less potential
261 for the POCT to prevent deaths by eliminating unnecessary hospitalization.

262

263 At the community level, the probability of referral acceptance overwhelmingly influenced the
264 impact of a POCT, dictating the possibility for accurate negative POCT diagnoses to avert
265 unnecessary hospitalization. Overall bacterial prevalence also shaped POCT impact, with greater
266 potential impact when prevalence was lower (i.e., when there were more healthy infants
267 benefitting from accurate non-referral).

268

269 ***Economic Analysis***

270 POCT implementation in hospitalized neonates reduced hospitalization days (**Supplement,**
271 **Figure S7**), cutting total care and treatment costs by 17%-43% at various levels of bacterial
272 prevalence, proportion of neonates eligible for discharge, and test performance. Greater cost
273 savings occurred at lower bacterial prevalence (6%) than higher prevalence (24%), highlighting

274 the value of identifying discharge-eligible neonates without infection with a POCT
275 (**Supplement, Figure S8-S9**). Cost savings did not perfectly mirror mortality trends **(Figure 2)**
276 as higher mortality led to fewer hospitalization days and thus lower costs.
277
278 Cost savings were more considerable following POCT implementation at the community level
279 (48%-81%) mainly by minimizing inappropriate referrals and hospitalization days. Fewer
280 inappropriate referrals occurred at baseline when bacterial prevalence was low, granting more
281 cost savings with POCTs. Across all levels of prevalence and discharge eligibility, cost savings
282 increased with better test performance (higher sensitivity and/or specificity) (**Supplement,**
283 **Figure S10-S11**). Excluding critically ill infants from the analysis raised the median allowable
284 POCT cost, from $0.86-$1 in India and $0.28-$0.33 in Uganda, across varied scenarios
285 (**Supplement, Figures S12-S13**).
286
287 To ensure the financial feasibility of implementing POCTs across all settings and ranges of
288 uncertainty, our analysis indicates that a globally acceptable neonatal sepsis POCT in hospital
289 settings should not exceed $21 USD. Likewise, to ensure cost neutrality in community settings,
290 the lowest of costs saved per test administered ($3) should be selected as the optimal cost at PHC
291 levels (**Supplement, Table S1-S2**). Results are reported following the Consolidated Health
292 Economic Evaluation Reporting Standards (**Supplement, Table S3**).

Discussion

Implementation of a sufficiently accurate POCT for sepsis detection in neonates or infants at hospital and community-level facilities can reduce overall morbidity and mortality and remain cost neutral when priced appropriately [10,14,33]. Although the exact impact of a POCT heavily depends on the specific use case implementation context, our modeling finds a test with at least 85% sensitivity and 80% specificity for hospitalized neonates and 90% sensitivity and 70% specificity for community-presenting infants is likely to reduce mortality.

If test sensitivity is lower than these values, deaths caused by missed diagnosis of true sepsis cases and ensuing antibiotic delays could increase overall mortality. However, there were instances where tests with low sensitivity and high specificity, due to large reductions in unnecessary hospitalization, antibiotic use, and HAI acquisition among uninfected patients, could reduce mortality and costs despite greater false-negative diagnoses. While the overall benefits of a POCT may outweigh the consequences of false-negative results in these scenarios, a test sensitivity well above 80% should remain the criterion, with a sensitivity of 90% serving as an ideal TPP standard. A POCT with low sensitivity would have limited utility in independently ruling out sepsis among neonates and infants.

Test specificity must also be sufficiently high to reduce unnecessary hospitalizations and HAIs. However, even a test with lower specificity will improve upon the standard-of-care, possibly tolerated in some contexts. In hospital settings, 80% specificity paired with 85% sensitivity generated a net reduction in deaths. Yet, in community settings, 70% specificity with 90% sensitivity reduced infant deaths in most scenarios, excluding contexts with low referral

316 acceptance (17%) and high bacterial prevalence (24%). Under these circumstances, even 100%
317 specificity is insufficient unless sensitivity reaches 98%, underscoring the need to evaluate
318 contextual factors when implementing POCTs.
319
320 Given the complexity in diagnosing sepsis in neonates and infants, a POCT may be used as part
321 of a diagnostic package, affecting overall diagnostic impact and modifying the requirements and
322 trade-offs between POCT sensitivity and specificity. A true POCT may be hard to develop, but a
323 near POCT could have less impact than modeled due to delayed results. The current biomarker
324 candidates for POCTs, including CRP, PCT, and SAA have all shown sensitivities below the
325 80% threshold identified in this analysis [12,34,35]. The POCT could be part of a clinical
326 algorithm incorporating signs, symptoms, and risk factors, lowering the required test
327 performance for net benefit. We also did not account for how positive POCT results might
328 improve antibiotic timing and outcomes beyond empiric therapy, suggesting additional
329 uncaptured benefits.
330
331 A key limitation of this analysis is that model parameters, assumptions, and costs were all
332 derived from tertiary hospital and PHC studies in India and Uganda and thus may not perfectly
333 represent other resource-limited settings. Blood culture was assumed to be 100% specific in
334 diagnosing true negatives, but culture contamination is common in these settings creating false-
335 positive results, potentially altering health outcomes. Likewise, the possibility of false-negative
336 results due to inadequate blood volume for optimal culture performance could also impact our
337 estimates. The model contains assumptions that may differ across diverse environments where
338 sepsis in neonates and infants is common, including bacterial prevalence, resistance profiles,

339 length of hospitalization, and HAI rates. To account for this variability, several parameters were
340 varied to improve model sensitivity and observe trends to inform the suggested values to be
341 included in the TPP for sensitivity, specificity, and costs. While we expect relative differences
342 between the POCT and baseline standard-of-care to be consistent, these results should be
343 interpreted with discretion as parameters continue to evolve with potential stock-outs of
344 appropriate antibiotic treatment and exponential AMR spread in resource-limited settings.
345
346 Additionally, simplifying assumptions regarding clinical management and outcomes were made,
347 which may not capture all challenges of clinical pathways in sepsis diangosis. For example,
348 infants may become lost to follow-up after PHC referral, incurring unknown health outcomes.
349 Patients were functionally dichotomized into those who were being appropriately treated with
350 antibiotics and untreated; in reality, treatment is complex, and there are clinical benefits to
351 continued antibiotic refinement that could not be incorporated here. Similarly, indirect long-term
352 benefits to implementing POCTs that exist are not explicitly modeled here, including reductions
353 in AMR spread and preservation of first-line antibiotics in low-resource settings. Finally, we
354 assumed the POCT performed as intended with respect to sensitivity and specificity but ignored
355 possible invalid results occurring from new technology. Clarifying diagnostic algorithms based
356 on available and developing technologies, and the clinical management that accompany them are
357 necessary for future accurate costing of these tools – especially as practical challenges (i.e.,
358 operational and supply chain procedures) are identified during prototype development and
359 implementation [36].
360

361 This modeling analysis aims to guide understanding of necessary test specifications to be
362 considered with other technical parameters (i.e., blood volume, sample preparation guidelines,
363 and result timelines) as a call for the development of a POCT as an aid to diagnose sepsis in
364 hospitalized neonates and community-presenting infants. An accurate POCT could improve time
365 to diagnosis and generate net reductions in hospital days, HAIs, and deaths, while promoting the
366 de-escalation of antimicrobials in resource-limited settings. Our results displayed a critical trade-
367 off between HAI-related deaths prevented and those caused by a false-negative diagnosis,
368 suggesting that a high sensitivity should be prioritized over specificity to avoid potential delays
369 in antibiotic initiation. Given the nature of the settings in which the POCT will be used, its cost
370 should not exceed $21 in hospital settings and $3 in community settings.
371
372 Future research should address the current gaps in data on the incidence and clinical management
373 of sepsis in both hospital and community settings [37]. Bridging this gap is essential to generate
374 robust, context-specific estimates of the impact of a POCT and its downstream effects on AMR
375 [38]. Key areas of investigation may include advancing blood culture capacity, expanding
376 polymerase chain reaction diagnostics and their accessibility, and validating the use of
377 biomarkers. Nonetheless, urgent investments in diagnostic development are needed to accelerate
378 access to diagnostic solutions for the vulnerable populations most impacted by neonatal sepsis.

Author Contributions

Conceptualization: BG, CF, BEN. Data curation: JMC, MAH. Methodology: JMC, MAH, KHG, SK, BEN. Formal analysis: JMC, MAH, KHG. Investigation: JMC, MAH, BG, BB VC, KHG. Supervision: BG, CF, BB, SK, BEN, KHG. Writing - original draft: JMC, MAH. Writing - review and editing: JMC, MAH, KHG, BG, BB, VC, SK, NS, GC, FF, CF, BEN.

Acknowledgements

Not applicable.

Potential Conflicts of Interest

FF is a trustee of Neotree, a UK registered charity that provides technology, software information, education and support to newborn healthcare workers and medical practitioners in low resource settings (charity number: 1186748). All other authors declare no conflict of interest. The funders had no role in the design of the study, the collection, analyses, or interpretation of data, the writing of the manuscript, or the decision to publish the results.

Patient Consent Statement

This research utilizes publicly available data from literature; therefore, patient consent and/or formal ethical approval was not required. However, ethical considerations were included throughout the research process as transparency was maintained in the reporting of our modeling methodology. This statement affirms our commitment to ethical conduct in research, even in the absence of formal approval.

Data Availability Statement

We acknowledge the importance of transparent and responsible data sharing to foster scientific collaboration and advance research. Code for the model is available using the following link: https://doi.org/10.6084/m9.figshare.c.7776176.v1.All data used for this study are presented in the manuscript and gathered from publicly available literature and therefore do not necessitate any information de-identification. For additional information, interested parties can contact JMC (j.m.chevalier@amsterdamumc.nl) or MAH (m.hansen@amsterdamumc.nl).

Funding

This work was supported via FIND by the UK Department of Health and Social Care as part of the Global AMR Innovation Fund (GAMRIF) and with support from the Ministry of Foreign Affairs of the Government of the Netherlands. GAMRIF is a One Health UK aid fund that supports research and development around the world to reduce the threat of antimicrobial resistance in humans, animals and the environment for the benefit of people in low- and middle-income countries (LMICs). The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health and Social Care. FF is supported by a Wellcome Trust Early Career Award (227076/Z/23/Z).

References

1. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis. Vol. 106, Archives of Disease in Childhood. BMJ Publishing Group; 2021. p. 745–52.

2. CME Info - Child Mortality Estimates [Internet]. [cited 2024 Oct 7]. Available from: https://childmortality.org/causes-of-death/data

3. Agarwal R, Chaurasia S, Sankar MJ, Yadav CP, Arya S, Kapil A, et al. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016 Oct;4(10):e752–60.

4. Celik IH, Hanna M, Canpolat FE, Pammi M. Diagnosis of neonatal sepsis: the past, present and future. Vol. 91, Pediatric Research. Springer Nature; 2022. p. 337–50.

5. Gude SS, Peddi NC, Vuppalapati S, Gopal SV, Ramesh HM, Gude SS. Biomarkers of Neonatal Sepsis: From Being Mere Numbers to Becoming Guiding Diagnostics. Cureus. 2022 Mar;

6. Rani U, Lewis LE, Chawla K, Naha A. Preventable contributors to the neonatal healthcare-associated infections: a uni-center analytical study from South India. F1000Research. 2022 Apr 25;11:454.

7. Kirby R, Palamountain K, Spotswood N, Goldfarb D. Use Cases Sepsis Diagnostic - Infection Prevention and Control [Internet]. Available from: https://www.unicef.org/supply/media/2946/file/sepsis-diagnostic-use-cases.pdf

8. Nisar YB, Aboubaker S, Arifeen SE, Ariff S, Arora N, Awasthi S, et al. A multi-country implementation research initiative to jump-start scale-up of outpatient management of possible serious bacterial infections (PSBI) when a referral is not feasible: Summary findings and implications for programs. PLoS ONE. 2022 Jun;17(6 June).

9. Roy S, Patil R, Apte A, Thibe K, Dhongade A, Pawar B, et al. Feasibility of implementation of simplified management of young infants with possible serious bacterial infection when referral is not feasible in tribal areas of Pune district, Maharashtra, India. PLoS ONE. 2020 Aug;15(8 August).

10. Gleeson B, Ferreyra C, Palamountain K, Jacob ST, Spotswood N, Kissoon N, et al. A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries. BMJ Glob Health. 2024 Sep 1;9(9):e015862.

11. Bengnér J, Quttineh M, Gäddlin PO, Salomonsson K, Faresjö M. Serum amyloid A - A prime candidate for identification of neonatal sepsis. Clin Immunol Orlando Fla. 2021 Aug;229:108787.

12. Sharma V, Grover R, Priyadarshi M, Chaurasia S, Bhat NK, Basu S, et al. Point-of-Care Serum Amyloid A as a Diagnostic Marker for Neonatal Sepsis. Indian J Pediatr. 2024 Jun;91(6):571–7.

456 13. Eichberger J, Resch E, Resch B. Diagnosis of Neonatal Sepsis: The Role of Inflammatory
457 Markers. Front Pediatr [Internet]. 2022 Mar 8 [cited 2025 Jul 3];10. Available from:
458 https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.840288/full

459 14. Lloyd LG, Dramowski A, Bekker A, Ballot DE, Ferreyra C, Gleeson B, et al. Multicentre
460 external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP)
461 score: a retrospective case–control study. BMJ Paediatr Open [Internet]. 2024 Oct 1 [cited
462 2025 Jun 24];8(1). Available from: https://bmjpaedsopen.bmj.com/content/8/1/e002748

463 15. Adatara P, Afaya A, Salia SM, Afaya RA, Konlan KD, Agyabeng-Fandoh E, et al. Risk
464 Factors Associated with Neonatal Sepsis: A Case Study at a Specialist Hospital in Ghana. Sci
465 World J. 2019;2019.

466 16. Kanimozhi P, Kumaravel K, Velmurugan K. A study on the length of stay of neonates in
467 neonatal intensive care unit in a referral hospital in India. Int J Contemp Pediatr. 6(2):746–9.

468 17. Schmatz M, Srinivasan L, Grundmeier RW, Elci OU, Weiss SL, Masino AJ, et al.
469 Surviving Sepsis in a Referral Neonatal Intensive Care Unit: Association between Time to
470 Antibiotic Administration and In-Hospital Outcomes. J Pediatr. 2020 Feb;217:59-65.e1.

471 18. Sisay EA, Mengistu BL, Taye WA, Fentie AM, Yabeyu AB. Length of Hospital Stay and
472 Its Predictors Among Neonatal Sepsis Patients: A Retrospective Follow-Up Study. Int J Gen
473 Med. 2022;15:8133–42.

474 19. Murki S, Vardhelli V, Deshabhotla S, Sharma D, Pawale D, Kulkarni D, et al. Predictors
475 of length of hospital stay among preterm infants admitted to neonatal intensive care unit: Data
476 from a multicentre collaborative network from India (INNC: Indian National Neonatal
477 Collaborative). J Paediatr Child Health. 2020 Oct;56(10):1584–9.

478 20. Mukhopadhyay R, Arora NK, Sharma PK, Dalpath S, Limbu P, Kataria G, et al. Lessons
479 from implementation research on community management of possible serious bacterial
480 infection (pSBI) in young infants (0-59 days), when the referral is not feasible in Palwal
481 District of Haryana, India. PLoS ONE. 2021 Jul;16(7 July).

482 21. Saha SK, Schrag SJ, Arifeen SE, Mullany LC, Islam MS, Shang N, et al. Causes and
483 incidence of community-acquired serious infections among young children in south Asia
484 (ANISA): an observational cohort study. The Lancet. 2018 Jul;392(10142):145–59.

485 22. World Health Organization. WHO recommendations for management of serious bacterial
486 infections in infants aged 0–59 days [Internet]. 2024. Available from:
487 https://www.who.int/publications/i/item/9789240102903

488 23. Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, et al. Delayed
489 Antimicrobial Therapy Increases Mortality and Organ Dysfunction Duration in Pediatric
490 Sepsis. Crit Care Med. 2014;42(11):2409–17.

491 24. Karambelkar G, Malwade S, Karambelkar R. Cost analysis of Healthcare in a Private
492 sector Neonatal Intensive Care Unit in India. Indian Pediatr. 2016 Sep 8;53(9):793–5.

493 25. Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for Inflation and
494 Currency Changes Within Health Economic Studies. Value Health. 2019 Sep;22(9):1026–32.

495 26. Nichols BE, Sigaloff KCE, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, et al.
496 Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of
497 drug-resistant HIV: A mathematical modelling study. J Int AIDS Soc. 2014;17(1).

498 27. Chauhan AS, Prinja S, Selvaraj S, Gupta A, Muraleedharan VR, Sundararaman T. Cost
499 of delivering primary healthcare services through public sector in India. Indian J Med Res.
500 2022 Sep;156(3):372–80.

501 28. Milton R, Gillespie D, Dyer C, Taiyari K, Carvalho MJ, Thomson K, et al. Neonatal
502 sepsis and mortality in low-income and middle-income countries from a facility-based birth
503 cohort: an international multisite prospective observational study. Lancet Glob Health. 2022
504 May;10(5):e661–72.

505 29. Ahmad A, Iram S, Hussain S, Yusuf NW. Diagnosis of paediatric sepsis by automated
506 blood culture system and conventional blood culture. JPMA J Pak Med Assoc. 2017
507 Feb;67(2):192–5.

508 30. Mathur P, Malpiedi P, Walia K, Srikantiah P, Gupta S, Lohiya A, et al. Health-care-
509 associated bloodstream and urinary tract infections in a network of hospitals in India: a
510 multicentre, hospital-based, prospective surveillance study. Lancet Glob Health. 2022
511 Sep;10(9):e1317–25.

512 31. Ting JY, Synnes A, Roberts A, Deshpandey A, Dow K, Yoon EW, et al. Association
513 between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants
514 without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr. 2016
515 Dec;170(12):1181–7.

516 32. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-
517 acquired neonatal infections in developing countries. The Lancet. 2005 Mar;365(9465):1175–
518 88.

519 33. Bansal A, Howes A, Arih I. P23 Advance market commitment for point of care
520 diagnostic focused on neonatal sepsis: estimating costs and effectiveness. JAC-Antimicrob
521 Resist. 2024 Aug 1;6(Supplement_2):dlae136.027.

522 34. Hisamuddin E, Hisam A, Wahid S, Raza G. Validity of C-reactive protein (CRP) for
523 diagnosis of neonatal sepsis. Pak J Med Sci. 2015;31(3):527–31.

524 35. Jafar H, Agarwal J, Kalyan RK, Radera S, Verma S, Kumar M, et al. Role of serum
525 procalcitonin as a marker for diagnosing neonatal sepsis. Int J Contemp Pediatr. 2019 Aug
526 23;6(5):1991–7.

527 36. Taneja R, Batra P. Biomarkers as point of care tests (POCT) in neonatal sepsis: A state of
528 science review. J Neonatal-Perinat Med. 2021;14(3):331–8.

529 37. Sturrock S, Sadoo S, Nanyunja C, Le Doare K. Improving the Treatment of Neonatal
530 Sepsis in Resource-Limited Settings: Gaps and Recommendations. Res Rep Trop Med. 2023
531 Dec 14;14:121–34.

532 38. Celik IH, Hanna M, Canpolat FE, Pammi M. Diagnosis of neonatal sepsis: the past,
533 present and future. Vol. 91, Pediatric Research. Springer Nature; 2022. p. 337–50.

534

535 **Figure 1.** Conceptual diagram for clinical cascade for a point-of-care test for neonatal sepsis at the primary health
536 care level and hospital. **POCT: point-of-care test, PHC: primary health care, FB: fast-breathing, CSI: clinical*
537 *severe infection, CI: critical illness, HAI: hospital-associated infection*
538



539

Figure 2. Percent reduction in neonatal deaths in a hospital setting, across modeled bacterial prevalence and proportion of neonates eligible for discharge, by test specificity and sensitivity, when **A)** the risk of hospital-associated infections is low (5%) or **B)** high (20%).



Figure 3. Percent of deaths averted compared to baseline when using the point-of-care test at the community level, by test sensitivity, specificity, bacterial prevalence, and referral acceptance, when A) HAI risk and mortality are low (5%, 12%), and B) HAI risk and mortality are high (20%, 29%)



Figure 4. Univariate sensitivity analysis of A) hospital model parameters or B) community model parameters and the correlated number of neonatal deaths averted, stratified by A) hospital-associated infection risk or B) hospital-associated infection risk and case fatality rate. The absolute number of deaths averted is shown on the X-axis, while the corresponding percentage is shown on the error bar label. The vertical red, dashed line represents the number of deaths averted when all other variables are held at their constant A) specificity: 80%, sensitivity: 85%, discharge eligibility: 35%, bacterial prevalence: 12% or B) specificity: 70%, sensitivity: 90%, referral acceptance: 37%, bacterial prevalence: 12%. **HAI: hospital-associated infection, CFR: case fatality rate*